Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
GenAI initiatives are complex and—in some cases—costly. “As such, the main rationale for pursuing them needs to be business growth, not workforce reductions.”
The authors of the survey report note that AI tools mentioned by respondents run the gamut from automated appointment reminders to dynamic “care gap” messaging.
Some AI decision-support models have a proclivity for recommending aggressive care pathways. And doing so on the basis of patient demographics, not medical necessity.
In exclusive interviews, HealthExec spoke with the American Cancer Society about rising cancer rates, and a virtual provider service that's working to bolster struggling oncology staff.
A data analysis from the Physicians Advocacy Institute and Avalere Health found corporate buyouts are leaving patients in low-population areas with fewer options, as doctors are opting to go elsewhere.
If healthcare AI is to flourish outside of academic research settings and industry R&D departments, it will need to win over its most difficult-to-impress audience: healthcare workers in hospitals.
It stands to reason that the branch of healthcare most reliant on the use of language in clinical practice would embrace large language AI. But is U.S. mental healthcare on board with the notion?
Malissa Wood, MD, associate chief of cardiology for diversity and equity at Massachusetts General Hospital, explains the role of health equity in cardiovascular care and what her health system is doing to address it.
A new analysis reveals that insurers could put between $228 million and $2.15 billion back in taxpayers’ pockets by purchasing a series of generic oncology medications at the same prices obtained by the Mark Cuban Cost Plus Drug Company.